Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL372189 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372671 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL365960 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372535 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372698 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL13684439 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL37496 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20917177 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21753855 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8146438 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115910621-A | Nano flower-shaped NiCoS/NTA composite material and preparation method and application thereof | 桂林电子科技大学 | 2023-04-04 | — | — | CN | claimed |
| US-20250214060-A1 | WATER-ABSORBING RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, ABSORBER, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2025-07-03 | — | — | US | disclosed |
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119486602-A | Formulation preparation | 利兹大学 | 2025-02-18 | — | — | CN | disclosed |
| EP-4501447-A1 | WATER-ABSORBING RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, ABSORBER, AND ABSORBENT ARTICLE | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2025-02-05 | — | — | EP | disclosed |
| EP-4463153-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | Eleusis Therapeutics US, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024206355-A2 | BIOCONTROL COMPOSITIONS AND METHODS | BOWLING GREEN STATE UNIVERSITY (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-113959822-B | Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application | 珠海市丽拓生物科技股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023190491-A1 | WATER-ABSORBING RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, ABSORBER, AND ABSORBENT ARTICLE | 住友精化株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023137094-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-1884097-A | Process for preparing sodium antimony sulfide microwires and array thereof | CHANGCHUN APPLIED CHEMISTRY (CN) | 2006-12-27 | — | — | CN | disclosed |
| CN-1860365-A | Method of immunoreaction measurement and, for use therein, reagent, kit and optical cell | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2006-11-08 | — | — | CN | disclosed |
| CN-1852739-A | Pharmaceutical products comprising bisphosphonates | NOVARTIS AG (CH) | 2006-10-25 | — | — | CN | disclosed |
| CN-1735400-A | Drug delivery system utilizing subconjunctival reservoir | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| CN-1183897-C | Reduction composition containing specific amino siloxane for treating keratin fiber | OREAL (FR) | 2005-01-12 | — | — | CN | disclosed |
| CN-1450893-A | Method for treatment of sepsis | LILLY CO ELI (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1416801-A | Reduction composition containing specific amino siloxane for treating keratin fiber | OREAL (FR) | 2003-05-14 | — | — | CN | disclosed |
| CN-1238691-A | Liquid alendronate preparation | MERCK & CO LTD (US) | 1999-12-15 | — | — | CN | disclosed |
| US-5928892-A | MUTANT FACTOR B WITH ONE OR MORE AMINO ACIDS IN SHORT CONSENSUS REPEAT DOMAIN OR VON WILLEBRAND FACTOR DOMAIN REPLACED BY CORRESPONDING REGION OF SECOND PROTEIN; ALTERED ACTIVITY; TREATMENT OF AUTOIMMUNE DISEASE; IMUNOSUPPRESSANTS | WASHINGTON UNIVERSITY (US) | 1999-07-27 | — | — | US | disclosed |
| CN-1083110-A | The microorganisms producing method of L-xitix | BIO TECH RESOURCES (US) | 1994-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | SRI, PROC, PRDX6 | MEN1 4470/4885ALDH1A1 1026/4885HMGCR 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.